MRK financials
Merck & Co., Inc. · end-of-day data as of Oct 16, 2026
Merck & Co., Inc.
$145.95+12.0%
Buy · 27 analystsPT $157.17 +7.7%
MRK reported revenue of $16.61B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 5.1% from a year earlier. It posted diluted EPS of -$0.54, free cash flow of $4.48B and a net margin of -8.0%.
Valuation
- P/E116.8x
- P/E vs own+187.9%
- P/E vs sector+314.7%
- FCF yield+4.5%
- Market cap$360B
Quarterly results
Q2 FY2026: Revenue +5.1% year over year, free cash flow 27.0% of revenue, operating margin -4.1%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $16.61B | -0.54 | $4.48B | 73.5% | -4.1% | -8.0% |
| Q1 FY2026 | Mar 31, 2026 | $16.29B | -1.72 | $2.93B | 81.9% | -11.6% | -26.0% |
| Q4 FY2025 | Dec 31, 2025 | $16.32B | 1.19 | $1.82B | 70.5% | 37.7% | 18.2% |
| Q3 FY2025 | Sep 30, 2025 | $17.18B | 2.32 | $6.83B | 75.6% | 43.4% | 33.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.8B | 1.76 | $2.53B | 75.7% | 40.2% | 28.0% |
| Q1 FY2025 | Mar 31, 2025 | $15.62B | 2.01 | $1.17B | 75.1% | 43.0% | 32.5% |
| Q4 FY2024 | Dec 31, 2024 | $15.62B | 1.48 | $2.51B | 75.5% | 27.8% | 24.0% |
| Q3 FY2024 | Sep 30, 2024 | $16.66B | 1.24 | $8.51B | 75.5% | 23.9% | 19.0% |
| Q2 FY2024 | Jun 30, 2024 | $16.11B | 2.14 | $4.85B | 76.8% | 38.0% | 33.9% |
| Q1 FY2024 | Mar 31, 2024 | $15.78B | 1.87 | $2.23B | 77.6% | 36.5% | 30.2% |
| Q4 FY2023 | Dec 31, 2023 | $14.63B | -0.48 | -$743M | 73.3% | -11.7% | -8.4% |
| Q3 FY2023 | Sep 30, 2023 | $15.96B | 1.86 | $6.82B | 73.3% | 36.8% | 29.7% |